Letter to the Shareholders – November 2018
We would like to use this opportunity to inform you that we have now started the human clinical safety trial in UK and the first patients are now enrolled…
We would like to use this opportunity to inform you that we have now started the human clinical safety trial in UK and the first patients are now enrolled…
We are very pleased to announce that we late yesterday received the permission from MHRA (UK health authorities) to start the CE mark human trial…
General meeting Biovotec AS 2018…
We are pleased to inform that we have now received another MNOK 10,0 (tranche 2 of 3 tranches) from the investor consortium that joined us last fall…
Biovotec AS completes planned placement of NOK…
Minutes of the annual general meeting of Biovotec AS…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.